摘要
目的探讨齐拉西酮治疗精神分裂症的临床疗效及安全性。方法东台市第三人民医院2008年2月至2011年7月收治的精神分裂症患者78例按就诊顺序随机分为观察组和对照组各39例,对照组给予利培酮,初始剂量为1mg/d,逐渐增加剂量,在l周之内剂量加至4mg/d。观察组给予齐拉西酮,初始剂量为20mg/d,逐渐增加剂量,在1周之内剂量加至每天120～140mg。在治疗前与治疗的2、4、8周末评价两组疗效及不良反应。结果两组患者经治疗后观察组总有效率为89.7%,对照组为87.2%,两组比较差异无统计学意义(P>0.05),治疗后PANSS评分较治疗前有明显下降(P<0.05),但两组间比较差异无显著性(P>0.05),且观察组不良反应较对照组轻微。结论齐拉西酮治疗精神分裂症的临床疗效显著,安全性高,尤其可以用于利培酮治疗效果较好但是锥体外系不良反应不能耐受的患者的维持治疗,以及首发的年轻女性患者的治疗。
Objective To explore the clinical efficacy and safety of Ziprasidone in treatment of schizophrenia.Methods The hospital from February 2008 to July 2011 were treated 78 patients with schizophrenia were randomly divided into two groups and the control group each 39 cases,the control group was given risperidone,the initial dose of 1mg/day,gradually increasing dose,the dose within the l-week increase to 4mg/day.Observation group were given ziprasidone,the initial dose of 20mg/day and gradually increase the dose,the dose increase within 1 week to a daily 120~140mg.Before treatment and treatment of 2,4,8 week efficacy and toxicity were evaluated.Results The two groups of patients after treatment total effective rate was 89.7%,87.2% of the control group,the difference was no statistically significant（P0.05）,PANSS score after treatment than before treatment significantly decreased（P0.05）,but the difference between the two groups was no significant（P0.05）,and the observation group than in the control group of minor adverse reactions.Conclusions Ziprasidone in treatment of schizophrenia clinical effect is significant,high security,in particular,can be used for risperidone in the treatment of extrapyramidal side effects better but can not tolerate maintenance treatment of patients,and the treatment,of the first young female patients.
出处
《医药论坛杂志》
2011年第23期32-33,36,共3页
Journal of Medical Forum
